Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14396537 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL5436113 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL24322495 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL318913 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL29646329 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL318914 | 0.98 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL14655321 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL5966926 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2PKMCYP3A4CYP2C19GAA | |
| SCHEMBL15045195 | 0.82 | L3MBTL3 (0.49) | CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL738198 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2PKMCYP3A4CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | claimed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | claimed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | claimed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | claimed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | claimed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | claimed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | claimed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | claimed |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-05-14 | — | — | US | claimed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | claimed |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2018-10-11 | — | — | US | claimed |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2018-07-24 | — | — | US | claimed |
| EP-2536285-B1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-04-25 | — | — | EP | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | claimed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | SMN1; SMN2 3632/4885PKM 1096/4885CYP3A4 79/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | SMN1; SMN2 3632/4885PKM 1096/4885CYP3A4 79/4885 |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | SMN1; SMN2 4041/4885PKM 758/4885CYP3A4 41/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | SMN1; SMN2 3147/4885PKM 1025/4885CYP3A4 63/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | SMN1; SMN2 3632/4885PKM 1096/4885CYP3A4 79/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | SMN1; SMN2 4191/4885PKM 733/4885CYP3A4 68/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | SMN1; SMN2 3583/4885PKM 858/4885CYP3A4 36/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | SMN1; SMN2 2139/4885PKM 3848/4885CYP3A4 4043/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | SMN1; SMN2 2890/4885PKM 3229/4885CYP3A4 3893/4885 |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | SMN1; SMN2 4041/4885PKM 758/4885CYP3A4 41/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | SMN1; SMN2 7/4885PKM 576/4885CYP3A4 1537/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | SMN1; SMN2 2083/4885PKM 3861/4885CYP3A4 4408/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | SMN1; SMN2 4191/4885PKM 733/4885CYP3A4 68/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | SMN1; SMN2 2139/4885PKM 3848/4885CYP3A4 4043/4885 |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | SMN1; SMN2 4041/4885PKM 758/4885CYP3A4 41/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | SMN1; SMN2 3583/4885PKM 858/4885CYP3A4 36/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | SMN1; SMN2 3632/4885PKM 1096/4885CYP3A4 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.